Selective Androgen Receptor Modulators (SARMs) - A Prohibited Class of Anabolic Agents. U.S. Anti-Doping Agency, November 18, 2015. https://www.usada.org/selective-androgen-receptor-modulators-sarms-prohibited-class-anabolic-agencts/. Accessed: August 30, 2017.

Dynamic Technical Formulations, LLC. Issues a Voluntary Nationwide Recall of Tri-Ton Due to the Presence of Andarine and Ostarine. FDA Recalls, Market Withdrawals, & Safety Alerts, May 19, 2017. https://www.fda.gov/Safety/Recalls/ucm559700.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed: Sept 7, 2017.

2017-18 NCAA Banned Drugs List. National Collegiate Athletic Association (NCAA), June 5, 2017. http://www.ncaa.org/2017-18-ncaa-banned-drugs-list. Accessed: Sept 7, 2017

Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017

Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017

Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45. View abstract.

Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2(3):153-61. View abstract.

Coss CC, Jones A, Dalton JT. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024 (enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest New Drugs 2016;34(4):458-67. View abstract.

Dubois V, Simitsidellis I, Laurent MR, et al. Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage. Endocrinology 2015;156(12):4522-33. View abstract.

Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical composition and labeling of substances marketed as selective androgen receptor modulators and sold via the internet. JAMA 2017;318(20):2004-10. View abstract.

Thevis M, Geyer H, Thomas A, Schänzer W. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal 2011;3(5):331-6. View abstract.

Dart DA, Kandil S, Tommasini-Ghelfi S, et al. Novel trifluoromethylated enobosarm analogues with potent antiandrogenic activity in vitro and tissue selectivity in vivo. Mol Cancer Ther 2018;17(9):1846-58. View abstract.

USADA. Athlete Advisory: Ostarine in Supplements. July 2017. Available at: https://www.usada.org/growing-evidence-ostarine-athlete-risk/.

FDA. FDA Warns against using SARMs in body building products. October 2017. Available at: https://www.fda.gov/newsevents/newsroom/fdainbrief/ucm583021.htm.

WADA. What is prohibited. 2019 list of prohibited substances and methods. Available at: https://www.wada-ama.org/en/content/what-is-prohibited/.

Leciejewska N, Pruszynska-Oszmalek E, Bien J, Nogowski L, Kolodziejski PA. Effect of ostarine (enobosarm/GTX024), a selective androgen receptor modulator, on adipocyte metabolism in Wistar rats. J Physiol Pharmacol 2019;70(4). View abstract.

Roch PJ, Henkies D, Carstens JC, et al. Ostarine and ligandrol improve muscle tissue in an ovariectomized rat model. Front Endocrinol (Lausanne) 2020;11:556581. View abstract.

Komrakova M, Furtwängler J, Hoffmann DB, Lehmann W, Schilling AF, Sehmisch S. The selective androgen receptor modulator ostarine improves bone healing in ovariectomized rats. Calcif Tissue Int 2020;106(2):147-157. View abstract.

Komrakova M, Nagel J, Hoffmann DB, Lehmann W, Schilling AF, Sehmisch S. Effect of selective androgen receptor modulator enobosarm on bone healing in a rat model for aged male osteoporosis. Calcif Tissue Int 2020;107(6):593-602. View abstract.

Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J 2021;8(1):e00518. View abstract.

Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- d) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine). Toxics 2021;9(10):251. View abstract.

Gheddar L, Raul JS, Kintz P. Development and validation of SARMs and metabolic modulators screening in hair using UHPLC-MS/MS: Application to a doping case and first identification of S23 in authentic human hair. J Chromatogr B Analyt Technol Biomed Life Sci 2021;1187:123048. View abstract.

Komrakova M, Büchler G, Böker KO, et al. A combined treatment with selective androgen and estrogen receptor modulators prevents bone loss in orchiectomized rats. J Endocrinol Invest 2022;45(12):2299-2311. View abstract.

Weinblatt D, Roy S. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator. J Med Cases 2022;13(5):244-248. View abstract.

Leciejewska N, Kolodziejski PA, Sassek M, Nogowski L, Malek E, Pruszynska-Oszmalek E. Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles. Int J Mol Sci 2022;23(8):4404. View abstract.

Roch PJ, Wolgast V, Gebhardt MM, et al. Combination of selective androgen and estrogen receptor modulators in orchiectomized rats. J Endocrinol Invest 2022;45(8):1555-1568. View abstract.